OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Namir is VP of the Infectious Diseases organisation and a member of the management team at Immunocore Ltd. In his time at the company, Namir has been responsible for building the biology and translational organisation to deliver novel immunotherapies, based on the company’s platform technology, into early phase trials. Namir has also been overseeing the first in human trial with the first in class IMCgp100 immunotherapy for the treatment of malignant melanoma and, is now overseeing the company’s Infectious Diseases Unit. Prior to joining Immunocore in April 2009, Namir was a Group Leader at GSK within Discovery Research, delivering novel assays for the screening of compounds targeting a variety of disease indications. Namir received his DPhil from the Cellular Immunology Unit at the University of Oxford, and has given talks, authored papers and book chapters on the application of immunotherapies to cancers and infectious diseases.
